Treatment of B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoma.
- Author:
Eun Sil PARK
1
;
Sang Duk KIM
;
Hyoung Jin KANG
;
Hyoung Soo CHOI
;
Hee Young SHIN
;
Hyo Seop AHN
Author Information
1. Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea. hsahn@snu.ac.kr
- Publication Type:Original Article
- Keywords:
B-cell acute lymphoblstic leukemia (B-ALL);
B-cell non-Hodgkin's lymphoma;
Chemotherapy;
Toxic complication
- MeSH:
B-Lymphocytes*;
Bone Marrow;
Consolidation Chemotherapy;
Cytarabine;
Doxorubicin;
Drug Therapy;
Etoposide;
Fever;
Follow-Up Studies;
Humans;
Induction Chemotherapy;
Leukemia;
Lymphoma, B-Cell*;
Lymphoma, Non-Hodgkin;
Methotrexate;
Neutropenia;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*;
Prednisolone;
Recurrence;
Renal Dialysis;
Stem Cells;
Stomatitis;
Survival Rate;
Tumor Burden;
Tumor Lysis Syndrome;
Vincristine
- From:Korean Journal of Pediatric Hematology-Oncology
2002;9(2):166-176
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We report here the improved survival rate of B-cell acute lymphoblstic leukemia (B-ALL) and B-cell non-Hodgkin's lymphoma (B-NHL) treated with a short, intensive multiagent chemotherapy and the treatment related toxicities and complications. METHODS: From Oct. 1997 to Apr. 2002, 10 patients were enrolled. Patients were classified into three groups (Group A, B, C) according to tumor burden and were treated with CCG 5961, UKCCSG 9600, and LMB96 protocol. Induction chemotherapy included cyclophsophamide, vincristine, prednisolone, doxorubicin and high dose (HD) methotrexate (COPADM). Consolidation chemotherapy included HD methotrexate, HD cytarabine and etoposide (CYM; group B, CYVE; group C). In one patient, HD chemotherapy with stem cell rescue was used because residual disease was detected after consolidation chemotheapy. RESULTS: Four patients were B-ALL and six patients were B-NHL (A; 1, B; 2, C; 7). Regimen was changed in 1 patient because of residual disease (B--
